• PMV Pharmaceuticals reported updated interim Phase 2 PYNNACLE results for rezatapopt in platinum-resistant or refractory ovarian cancer.
• Results were already released from a May 14, 2026 cutoff; broader cohort updates are scheduled for a fourth-quarter 2026 medical conference.
• Patients showed meaningful tumor shrinkage with durable benefit, supporting the drug’s potential as a monotherapy in this hard-to-treat setting.
• Safety remained broadly consistent across cohorts, with most side effects described as mild to moderate.
• FDA feedback backed an accelerated-approval filing strategy; an NDA submission is planned for the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMV Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608311601PRIMZONEFULLFEED9818791) on August 31, 2026, and is solely responsible for the information contained therein.